Spine Fusion News and Research

RSS

ETEX' Equivabone receives additional FDA clearance for use in posterolateral spine fusion

ETEX Corporation, an advanced biomaterials company, announced today additional FDA 510(k) cleared indications for EquivaBone®. EquivaBone was the first FDA cleared hard-setting osteoinductive material and is the only osteoinductive bone graft substitute that provides a continuous nanocrystalline calcium phosphate scaffold.

3 Oct 2009

Neck surgery for cervical spine disorders alleviates headaches

A new study published in the August 2009 issue of the Journal of Bone and Joint Surgery (JBJS) finds that two years after anterior cervical neck operations, patients who have arthroplasty (disc replacement) or arthodesis (spine fusion) can be expected to have significant improvement in their headache symptoms.

3 Aug 2009

Biocomposites granted SFDA clearance for geneX in China

Biocomposites announced today that the company's unique bone graft substitute geneX , has been cleared for use by the State Food and Drug Administration (SFDA) of the People's Republic of China.

22 Feb 2009

Cost effectiveness of spinal surgery examined

Back pain affects more than 80 percent of people and costs more than $100 billion annually in the U.S. But is the surgery cost effective?

30 Dec 2008

European market for bone morphogenic proteins in spine fusion

High growth is forecast for novel technologies used either as adjuncts or as alternatives to current surgical procedures for the fusion of spinal vertebrae. Bone morphogenic proteins (BMP) - a new and innovative class of natural growth factors - represent amongst the most exciting of these niches.

20 Dec 2004